Scientific publications
Satelia® Cardio
Published studies on remote monitoring of chronic heart failure with Satelia® Cardio: population, methods, results and limitations.
Major results
Nationwide analyses based on French National Health Insurance data (SNDS).
TELESAT-HF
95% CI 0.59–0.70; p < 0.0001
That is a 36% lower risk of death in monitored patients: an association observed in real life, consistent across sex, age, severity and digital literacy.
- Question
- Is remote monitoring with Satelia® Cardio associated with all-cause mortality at national scale?
- Population
- 18,882 heart failure patients from more than 300 hospital and community centres: 5,357 monitored, 13,525 on standard care; mean age 71.8.
- Methods
- Nationwide cohort on SNDS data, from 1 August 2018 to 31 December 2022, propensity score analysis (NCT06312501).
- Other results
- Heart failure hospitalisations: no significant difference (RR 0.95; 0.89–1.02). Emergency visits: RR 0.83 (0.75–0.92). Time spent in hospital: −2.1%. Intensive care admissions: RR 0.84 (0.74–0.97).
Characteristics after propensity score weighting (table 1 of the article). TELESAT-HF, Eur J Heart Fail, 2025.
NNT = 10.5 to prevent one death at 30 months
Kaplan-Meier, curve redrawn from figure 3A of the article (vertical axis from 50%). TELESAT-HF, Eur J Heart Fail, 2025.
Weighted HR for the overall population, adjusted HRs for subgroups (table 2 of the article). Outpatients: no heart failure hospitalisation in the previous 12 months. LTI: long-term illness status for heart failure. TELESAT-HF, Eur J Heart Fail, 2025.
TELESAT-HF, Eur J Heart Fail, 2025. Hazard ratio (HR) for mortality, rate ratio (RR) for events.
TELESAT PRIOR-HF
95% CI 0.47–0.63; p < 0.001
That is a 46% lower risk of death in monitored patients (23.5% vs 39.6% deaths during follow-up): an association observed in real life.
- Question
- Is remote monitoring associated with better survival in patients recently hospitalised for heart failure?
- Population
- 3,579 patients hospitalised for heart failure in the previous 12 months: 1,258 monitored with Satelia® Cardio, 2,321 on standard care; mean age 73, 33% women.
- Methods
- Prespecified analysis of TELESAT-HF on SNDS data (August 2018 – December 2022), propensity score weighting, mean follow-up of about 20 months.
- Other results
- Heart failure hospitalisations: RR 0.85 (0.78–0.94). Admissions via emergency department: RR 0.68 (0.59–0.78). Intensive care admissions: RR 0.65 (0.53–0.79). Mean total healthcare costs: no significant difference at 6, 12 and 24 months.
NNT = 6.2 to prevent one death at 30 months
Kaplan-Meier, curve redrawn from the article figure (vertical axis from 50%). TELESAT PRIOR-HF, Eur J Heart Fail, 2026.
Neutral cost: no significant difference at 6, 12 and 24 months
Remote monitoring fees included. Amounts are numerically higher at 12 and 24 months in monitored patients, with no significant difference. TELESAT PRIOR-HF, Eur J Heart Fail, 2026.
Each dot is a patient; filled dots are deaths observed during follow-up: 39.6% on standard care vs 23.5% with remote monitoring, rounded. The adjusted hazard ratio (0.54) reflects a 46% lower instantaneous risk of death.
TELESAT PRIOR-HF, Eur J Heart Fail, 2026. Mean total healthcare costs: no significant difference at 6, 12 and 24 months.
Other results in three figures
A hospital programme, the safety of the algorithm and the patient experience.
Readmissions one year after enrolment
heart failure readmissions in the year after enrolment.
Preliminary single-centre results (Médipôle Lyon-Villeurbanne), presented at a conference.
Negative predictive value of the algorithm
negative predictive value at seven days: when there is no alert, no hospitalisation follows.
Distribution of answers by the alert level computed by the algorithm. Questionnaire response rate: 90.9%.
Patient satisfaction
find the Satelia® Cardio application easy to use.
Share of patients answering “yes”. Patients less comfortable with digital tools receive phone-assisted follow-up.
All publications
Peer-reviewed articles, from the most recent to the oldest.
TELESAT PRIOR-HF: mortality and use of care after a heart failure hospitalisation
Key finding. Among 3,579 patients hospitalised for heart failure in the previous year, all-cause mortality was lower with remote monitoring (HR 0.54; 95% CI 0.47–0.63), with no significant difference in mean total healthcare costs at 6, 12 and 24 months.
Study summary
Prespecified analysis of TELESAT-HF restricted to patients hospitalised for heart failure in the year before inclusion. Using SNDS data and propensity weighting, about 1,258 monitored patients were compared with 2,321 patients on standard care. Remote monitoring was associated with lower all-cause mortality (23.5% vs 39.6%; HR 0.54), fewer heart failure readmissions (RR 0.85) and fewer days in hospital. Mean total healthcare costs did not differ significantly at 6, 12 and 24 months. Associations were consistent across age, sex and monitoring modality.
Summary written by Satelia from the published article.
Diabetes and mortality in a nationwide cohort of monitored patients
Key finding. Among 16,556 monitored patients, diabetes was associated with moderately higher mortality (HR 1.16; 95% CI 1.06–1.27), no longer significant after adjustment for NYHA class.
Study summary
Retrospective cohort of adults followed in the Satelia® Cardio programme from 2018 to 2024 (NCT07561866): 16,556 patients, 28.5% with diabetes. Diabetes was associated with higher mortality in models without NYHA class, especially before age 75; the association weakened and was no longer significant after adjustment for NYHA class, available in a subgroup. Mortality was more closely related to severity, comorbidities and cumulative aetiologies. High ten-day weight variability, measured through monitoring, was associated with poorer survival: an exploratory marker.
Summary written by Satelia from the published article.
Experience reported by 1,378 patients, from the ETAPES pilot to routine reimbursement
Key finding. Under routine reimbursement, overall satisfaction was 80.3% among 978 patients surveyed in 2024, vs 77.0% in the 2020-2021 reference cohort (non-significant difference).
Study summary
Two independent surveys of Satelia® Cardio users: 400 digitally literate patients in 2020-2021, during the ETAPES programme, and 978 patients in 2024, after routine reimbursement began. Overall satisfaction remained high (80.3% vs 77.0%, non-significant difference) and 70.3% of respondents would recommend the service. In 2024, 30.1% of respondents were aged 80 or over; usability ratings were slightly lower in this group. As the two samples differ, no causal conclusion can be drawn.
Summary written by Satelia from the published article.
Vaccination in monitored patients: reported knowledge and uptake
Key finding. Among 1,100 monitored patients surveyed in November 2025, 87.5% considered vaccination useful; for the 2025–2026 season, 62.2% reported influenza vaccination and 31.4% a COVID-19 booster.
Study summary
Electronic survey conducted from 5 to 28 November 2025 among Satelia® Cardio patients using the app: 1,100 respondents out of 4,856 invited (22.7%), mean age 71.5 years. 96% knew where to get vaccinated and 55.1% wanted reminders through remote monitoring. Lifetime reported vaccination was lower: 38.5% for the diphtheria-tetanus-pertussis-polio booster, 34.5% for pneumococcal vaccination and 11.5% for herpes zoster. Self-reported, descriptive data that identify groups to target in future prevention initiatives.
Summary written by Satelia from the published article.
SGLT2 inhibitor prescription in monitored patients: trends from 2021 to 2024
Key finding. Among 13,660 patients enrolled from 2021 to 2024, 64.4% were receiving an SGLT2 inhibitor at programme entry; prescription rose sharply after each major trial and guideline update, but remained lower in patients with chronic kidney disease.
Study summary
Analysis of adults with chronic heart failure enrolled in the nationwide Satelia® Cardio remote monitoring programme between 2021 and 2024 (NCT07022379): 13,660 patients, median age 78, 46% with reduced ejection fraction. SGLT2 inhibitor prescription at enrolment followed the major trials and ESC guidelines, with phenotype-specific patterns. It was more frequent in patients with diabetes, with a home-visiting nurse and in university hospitals, and less frequent with mildly reduced or preserved ejection fraction and chronic kidney disease, leaving room for optimisation.
Summary written by Satelia from the published article.
Elder-SAT: predictors of early events in older patients after a hospitalisation
Key finding. Among 156 patients with a mean age of 86, 27.6% died or had an unplanned readmission within 90 days of discharge; elevated pulmonary arterial pressure was an independent predictor (adjusted HR 2.56; 95% CI 1.10–5.98), unlike ejection fraction and frailty.
Study summary
Single-centre retrospective cohort (cardiogeriatric unit, La Porte Verte hospital, Versailles) of 156 patients aged 65 and over hospitalised for acute heart failure and discharged with follow-up combining comprehensive geriatric assessment and Satelia® Cardio remote monitoring. Within 90 days, 7.1% died and 20.5% had an unplanned readmission. Elevated pulmonary arterial pressure was associated with these events; ejection fraction, classical geriatric markers and frailty were not independently associated. A preserved metabolic profile was associated with fewer readmissions.
Summary written by Satelia from the published article.
REACT-HF: readmissions of very old patients in a cardiogeriatric pathway
Key finding. Among 255 patients (median age 87) followed with Satelia® Cardio in a cardiogeriatric pathway, 24.7% were readmitted for heart failure within 12 months; at least moderate mitral regurgitation, absolute iron deficiency and COPD were associated with readmission.
Study summary
Single-centre retrospective cohort (cardiogeriatric department, Greater Paris area) of patients aged 65 and over enrolled in Satelia® Cardio remote monitoring at discharge after an acute heart failure hospitalisation, from April 2023 to August 2025, within a pathway combining coordinated outpatient follow-up and day-hospital care. Of 991 patients enrolled, 255 had sufficient 12-month follow-up. Heart failure readmissions reached 9.8% at 3 months, 16.1% at 6 months and 24.7% at 12 months; discharge loop diuretic dose, mitral regurgitation, iron deficiency and COPD were associated with readmission. A descriptive study without a control group: it does not allow conclusions on the effect of remote monitoring.
Summary written by Satelia from the published article.
TELESAT-HF: all-cause mortality at national scale
Key finding. Across 18,882 patients from more than 300 centres, all-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70); no significant difference in heart failure hospitalisations.
Study summary
Nationwide real-world cohort built on SNDS data from August 2018 to December 2022 (NCT06312501): 5,357 patients followed with Satelia® Cardio and 13,525 on standard care, from more than 300 centres, compared after propensity weighting. Follow-up combines a web interface with nurse phone monitoring for patients less comfortable with digital tools. All-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70), with no difference in heart failure hospitalisations (RR 0.95), and fewer emergency visits and less time in hospital.
Summary written by Satelia from the published article.
Remote monitoring of patients with a left ventricular assist device (LVAD)
Key finding. Among 161 patients with a left ventricular assist device followed in nine university hospitals, adherence was 79% over a mean follow-up of nearly 20 months.
Study summary
Nationwide retrospective study in nine university hospitals describing remote follow-up of 161 patients with a left ventricular assist device through a dedicated application. Mean age was 62; half of the patients were implanted as a bridge to transplant. Over a mean follow-up of 19.9 months, adherence reached 79%; the algorithm issued orange and red alerts, 48.5% of which were resolved. The authors conclude that remote follow-up is feasible in this subpopulation and call for prospective studies on survival and quality of life.
Summary written by Satelia from the published article.
Experience and barriers reported by hospital teams
Key finding. In three hospitals in Nouvelle-Aquitaine (379 patients included), the barriers reported by clinicians were organisational: staffing, alert management and training of dedicated nurses.
Study summary
Descriptive study conducted from October 2022 to April 2023 in three hospitals, covering 379 heart failure patients (mean age 75.2) enrolled in a remote monitoring service. Semi-structured interviews with one cardiologist and two nurses describe broadly positive acceptance and barriers that are all organisational: staffing, handling alerts within tight schedules, initial reluctance from hospital administration, and the need for dedicated, trained nurses. The number of professionals interviewed is small.
Summary written by Satelia from the published article.
Clinical impact and good practice: a case report
Key finding. A reference weight entered incorrectly at enrolment silenced monitoring for fifteen months: enrolling a patient must be prepared as a step of the care pathway.
Study summary
Case of a 74-year-old patient followed at Cochin Hospital (AP-HP, Paris) for heart failure, hospitalised seven times in fifteen months without any remote monitoring alert. During the last stay, a telehealth nurse found that the reference weight entered at enrolment was wrong; after correction, no new episode occurred. The authors draw a good-practice rule: enrolling a patient means reviewing their care pathway, not just registering them. A single case, which cannot be generalised.
Summary written by Satelia from the published article.
Perceptions and satisfaction of monitored patients
Key finding. Among 825 patients, overall satisfaction was 87%; 98.1% of the 425 patients followed by phone found this follow-up simple and quick.
Study summary
Voluntary self-reported survey conducted during the ETAPES programme among 825 patients: 400 used the web application on their own and 425 were followed by phone with a nurse. 87% reported being satisfied, 94% found the application easy to use and 70% felt it helped their doctor follow them. 98.1% of patients followed by phone found this follow-up simple and quick. The authors highlight the need for assisted follow-up for patients less comfortable with digital tools.
Summary written by Satelia from the published article.
Safety and performance of the algorithm in real life
Key finding. Among 331 patients, the algorithm’s negative predictive value for hospitalisation within seven days was 99.43%.
Study summary
Retrospective observational study of 331 patients followed with Satelia® Cardio for more than six months between September 2018 and June 2020, under ETAPES: 36,682 questionnaires, with a 90.9% response rate. The algorithm classifies each answer as green, orange or red: 95.3% of answers were green, 4.5% orange and 0.2% red. Its negative predictive value for hospitalisation within seven days was 99.43%. The study assesses the algorithm’s safety, i.e. how reliable the absence of an alert is, not its clinical effect.
Summary written by Satelia from the published article.
ETAPES and Satelia® Cardio: an innovative funding programme
Key finding. Description of the ETAPES pilot funding programme and its implementation with Satelia® Cardio, before remote monitoring entered routine reimbursement in 2023.
Study summary
Descriptive analysis, based on public official documents, of the ETAPES pilot funding programme (created in 2016, operational from 2018) and of the Satelia® Cardio solution. It details eligibility criteria for heart failure patients and the required therapeutic education, and notes that Satelia® Cardio relies on patient-reported symptoms, without any connected device. The ETAPES programme ended on 31 December 2022.
Summary written by Satelia from the published article.
Reading these studies critically
What you need to know to interpret the evidence.
All results are listed
This page lists all peer-reviewed work published on Satelia® Cardio, whether the results are favourable or neutral.Observational studies
The nationwide analyses compare monitored and non-monitored patients in real life. No randomised trial has been published to date, and no study compares remote monitoring solutions with one another.Declared conflicts of interest
Several authors are employees or collaborators of NP Medical, the manufacturer of Satelia® Cardio. Declarations are included in each publication.Frequently asked questions
Is remote monitoring with Satelia® Cardio associated with lower mortality?
In TELESAT-HF (18,882 patients), all-cause mortality was lower in monitored patients (HR 0.64; 95% CI 0.59–0.70). This is an association observed in real life, not a randomised trial.
Where can I read the full articles?
Each publication links to the journal through its DOI; summaries are available on this site for the main studies.
How can I propose a research project?
Satelia’s medical department reviews collaboration proposals and data access requests.
A research project?
Working on heart failure remote monitoring, or want to discuss a study? Write to our medical department.